Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
Peer-reviewed research on semaglutide across obesity, type 2 diabetes, and cardiovascular outcome trials.
What does the research say about Semaglutide?
Semaglutide is among the most studied GLP-1 receptor agonists. Literature spans SELECT, SUSTAIN, STEP, and mechanistic work on receptor signaling and adipose/ cardiovascular endpoints.
Synapse surfaces peer-reviewed research and researcher networks for informational purposes only. This page does not provide medical advice, dosing guidance, or treatment recommendations.
Research feed: Semaglutide
11 indexed papers matched to curated MeSH concepts in the last 90 days.
Readability and understandability of online patient education on semaglutide
Evaluative analysis of readability and understandability in online semaglutide education, indicating a need for revision.
Semaglutide in the Era of Blockbuster Pharmaceuticals: A Narrative Review of Clinical, Economic, and Policy Dimensions
Narrative review examines semaglutide's clinical benefits and economic impact, highlighting regulatory challenges.
05 Effect Of Semaglutide Formulations On QTc Interval: A Retrospective Comparison Of Wegovy And Ozempic In A Tertiary Care Hospital
Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk
Observational analysis reveals sex- and formulation-specific risk of ischemic optic neuropathy with semaglutide, suggesting important safety concerns.
Semaglutide Hype or Hope: Evidence-based Review in Diabesity
Review highlights Semaglutide's impact on glycemic control and safety in type 2 diabetes, suggesting effective management for diabesity.
2657-P: Who Shapes the GLP-1 Narrative on TikTok: A Cross-Sectional Content Analysis
Cross-sectional analysis identifies engaging GLP-1 content themes from TikTok creators, suggesting implications for patient education.
Shrinking appetites: Will GLP-1 adoption in high-income countries accelerate Big Food’s push into low- and middle-income countries?
Randomized trial shows potential GLP-1 demand shift could worsen diet-related diseases in LMICs, indicating policy intervention is needed.
Semaglutide-associated Twiddler syndrome.
Semaglutide-induced rapid weight loss of 25 kg in a patient with an ICD led to Twiddler syndrome and right ventricular lead dysfunction.
May warrant monitoring in semaglutide-treated device patients; hypothesis-generating case report leaves need for prospective confirmation open.
The “Ozempic® Limb”
Case reports demonstrate complications from GLP-1 RAs in individuals with prosthetic limbs, suggesting the need for tailored treatment strategies.
From Weight Loss to Legal Loss: How Wegovy Exposed a Hidden Patent Exception
This article evaluates patent gaps in drug compounding under US law, suggesting potential reforms.
Researchers studying Semaglutide
Researcher network data is loading or unavailable for this topic.
Follow Semaglutide literature with AI-enriched clinical evidence on Synapse.
Search Semaglutide on SynapsePowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers